title: Beyond the letter of the law: the US Federal Circuit interprets section 271(g)(1)
authors.forename: R
authors.initials: R
authors.lastname: Tsao
authors.forename: E A
authors.initials: EA
authors.lastname: Hurley
mesh_terms: D001709:Biotechnology / Q000331:legislation & jurisprudence*; D002433:Cefaclor; D004345:Drug Industry / Q000331:legislation & jurisprudence*; D017239:Paclitaxel; D010330:Patents as Topic / Q000331:legislation & jurisprudence*; D011994:Recombinant Proteins; D014481:United States
chemical_list: D011994:Recombinant Proteins; D002433:Cefaclor; D017239:Paclitaxel